75% of consumers stop purchasing from a retailer due to delivery miscommunications
Research reveals UK delivery customer experience epidemic, with retailers losing customers due to poor post-purchase…
Research reveals UK delivery customer experience epidemic, with retailers losing customers due to poor post-purchase…
By partnering with Amdaris software developers, RightIndem augmented its existing software expertise and enhanced its…
Netacea reveals how the partnership contributed to evolving its product suite and helped cut onboarding…
OSLO, Norway, Sept. 16, 2021 /PRNewswire/ — Opera GX is introducing iCUE integration that makes CORSAIR…
PRESS RELEASE Launch of Oxitope Pharma, a biopharmaceutical start-up dedicated to the discovery and development…
Metastatic castration-resistant prostate cancer (mCRPC): 21 of 39 patients (54%) achieved ≥ 50% prostate-specific antigen…
21 of 40 patients (53%) achieved confirmed responses by independent review, exceeding prespecified futility boundary…
Safety Data Help Establish Part B Dose Expansion and Phase 2 Dose; Data showed encouraging…
Interim results from ongoing Phase 1 dose-escalation study demonstrate safety and tolerability of repeat dosing…
This announcement contains inside information for the purposes of Article 7 of the Market Abuse…
RESEARCH TRIANGLE PARK, N.C., Sept. 15, 2021 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX)…
TORONTO, Sept. 15, 2021 (GLOBE NEWSWIRE) — Mountain Valley MD Holdings Inc. (the “Company” or…
BXCL701 plus KEYTRUDA® (pembrolizumab) demonstrates encouraging anti-tumor activity in heavily pre-treated mCRPC patients with adenocarcinoma…
REDWOOD CITY, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) — Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage…
BOSTON, Sept. 15, 2021 (GLOBE NEWSWIRE) — X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in…
ERYTECH to Host on September 21, 2021 Second Quarter 2021 conference call and Business Update…
CAMBRIDGE, Mass., Sept. 15, 2021 (GLOBE NEWSWIRE) — Casma Therapeutics, Inc., a biotechnology company harnessing…
Vifor Pharma obtains exclusive commercialization rights for sparsentan in Europe, Australia and New Zealand Travere…
Publication Details the Discovery and Preclinical Profile of ETX0462, a First-in-Class Candidate Against Multidrug-Resistant Pathogens…
SANTA MONICA, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) — BioVie Inc., (NASDAQ: BIVI) (“BioVie” or…